Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2009

01-09-2009 | Original Article

Extracellular NM23-H1 protein inhibits the survival of primary cultured normal human peripheral blood mononuclear cells and activates the cytokine production

Authors: Junko Okabe-Kado, Takashi Kasukabe, Yoshio Honma, Hirofumi Kobayashi, Nobuo Maseki, Yasuhiko Kaneko

Published in: International Journal of Hematology | Issue 2/2009

Login to get access

Abstract

An elevated serum level of NM23-H1 protein is found in acute myelogenous leukemia (AML) and predicts a poor treatment outcome for AML patients. To investigate the potential pathological link between the elevated serum level of this protein and poor prognosis, we examined the extracellular effects of recombinant NM23-H1 protein on the in vitro survival of primary cultured normal peripheral blood mononuclear cells (PBMNC) at concentrations equivalent to the levels found in the serum of AML patients. Extracellular NM23-H1 protein inhibited the in vitro survival of PBMNC and promoted the production of various cytokines, such as GM-CSF and IL-1β, which in fact promoted the growth of primary cultured AML cells. These findings indicate a novel biological action of extracellular NM23-H1 and its association with poor prognosis of patients with elevated serum levels of NM23-H1 protein. These results suggest an important role of extracellular NM23-H1 in the malignant progression of leukemia and a potential therapeutic target for these malignancies.
Literature
1.
Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80:200–4.CrossRefPubMed
2.
Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr. 2000;32:247–58.CrossRefPubMed
3.
Lascu I, Gonin P. The catalytic mechanism of nucleoside diphosphate kinases. J Bioenerg Biomembr. 2000;32:237–46.CrossRefPubMed
4.
MacDonald NJ, De La Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer. 1995;31A:1096–100.CrossRefPubMed
5.
De La Rosa A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. Bioessays. 1995;17:53–62.CrossRef
6.
Horak CE, Lee JH, Elkahloun AG, et al. Nm23–H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res. 2007;67:7238–46.CrossRefPubMed
7.
Lacombe ML, Sastre-Garau X, Lascu I, et al. Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumors. Eur J Cancer. 1991;27:1302–7.CrossRefPubMed
8.
Ferenc T, Lewinski A, Lange D, Niewiadomska H, Sygut J, Sporny S, et al. Analysis of NM23–H1 protein immunoreactivity in follicular thyroid tumors. Pol J Pathol. 2004;55:149–53.PubMed
9.
Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastoma. Oncogene. 1993;8:855–65.PubMed
10.
Yokoyama A, Okabe-Kado J, Wakimoto N, et al. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematological malignancies. Blood. 1998;91:1845–51.PubMed
11.
Niitsu N, Okabe-Kado J, Okamoto M, et al. Serum nm23–H1 protein as a prognostic factor in aggressive non-Hodgkin’s lymphoma. Blood. 2001;97:1202–10.CrossRefPubMed
12.
Okabe-Kado J, Hayashi M, Honma Y, Hozumi M. Characterization of differentiation inhibitory activity from nondifferentiating mouse myeloid leukemia cells. Cancer Res. 1985;45:4848–52.PubMed
13.
Okabe-Kado J, Kasukabe T, Honma Y, Hozumi M. Purification of a factor inhibiting differentiation from conditioned medium of nondifferentiating mouse myeloid leukemia cells. J Biol Chem. 1988;263:10994–9.PubMed
14.
Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Henzel WJ, Hozumi M. Identity of differentiation inhibiting factor for mouse myeloid leukemia cells with Nm23 protein involved in tumor metastasis. Biochem Biophys Res Commun. 1992;182:987–94.CrossRefPubMed
15.
Yokoyama A, Okabe-Kado J, Sakashita A, et al. Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. Blood. 1996;88:3555–61.PubMed
16.
Wakimoto N, Yokoyama A, Okabe-Kado J, Nagata N, Motoyoshi K, Honma Y. Combined analysis of differentiation inhibitory factor nm23–H1 and nm23–H2 as prognostic factors in acute myeloid leukaemia. Br J Cancer. 1998;77:2298–303.CrossRefPubMedPubMedCentral
17.
Yamashiro S, Urano T, Shiku H, Furukawa K. Alteration of nm23 gene expression during the induced differentiation of human leukemia cell lines. Oncogene. 1994;9:2461–8.PubMed
18.
Willems R, Van Bockstaele DR, Landon F, et al. Decrease in nucleoside diphosphate kinase expression during hematopoietic maturation. J Biol Chem. 1998;273:13663–8.CrossRefPubMed
19.
Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23–H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood. 1999;94:3541–50.PubMed
20.
Niitsu N, Okabe-Kado J, Nakayama M, et al. Plasma levels of the differentiation inhibitory factor nm23–H1 protein and their clinical implications in acute myelogenous leukemia. Blood. 2000;96:1080–6.PubMed
21.
Okabe-Kado J, Kasukabe T, Honma Y, Hanada R, Nakagawara A, Kaneko Y. Clinical significance of serum NM23–H1 protein in neuroblastoma. Cancer Sci. 2005;96:653–60.CrossRefPubMed
22.
Okabe-Kado J, Kasukabe T. Physiological and pathological relevance of extracellular NM23/NDP kinases. J Bioenerg Biomembr. 2003;35:89–93.CrossRefPubMed
23.
Willems R, Slegers H, Rodrigus I, et al. Extracellular nucleoside diphosphate kinase NM23/NDPK modulates normal hematopoietic differentiation. Exp Hematol. 2002;30:640–8.CrossRefPubMed
24.
Okabe-Kado J, Kasukabr T, Baba H, Urano T, Shiku H, Honma Y. Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells. Biochim Biophys Acta. 1995;1267:101–6.CrossRefPubMed
25.
Urano T, Furukawa K, Shiku H. Expression of nm23/NDP kinase proteins on the cell surface. Oncogene. 1993;8:1371–6.PubMed
26.
Anzinger J, Malmquist NA, Gould J, Buxton ILO. Secretion of nucleoside diphosphate kinase (Nm23–H2) by cells from human breast, colon, pancreas and lung tumors. Proc West Pharmacol Soc. 2001;44:61–3.PubMed
27.
Rumjahn SM, Javed MA, Wong N, Law WE, Buxton ILO. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer. 2007;97:137280.CrossRef
28.
Keller M, Rüegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 2008;132:818–31.CrossRefPubMed
29.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.CrossRefPubMed
30.
Seong PY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469–78.CrossRefPubMed
Metadata
Title
Extracellular NM23-H1 protein inhibits the survival of primary cultured normal human peripheral blood mononuclear cells and activates the cytokine production
Authors
Junko Okabe-Kado
Takashi Kasukabe
Yoshio Honma
Hirofumi Kobayashi
Nobuo Maseki
Yasuhiko Kaneko
Publication date
01-09-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0384-4

Other articles of this Issue 2/2009

International Journal of Hematology 2/2009 Go to the issue

Case Report

Superwarfarin intoxication: hematuria is a major clinical manifestation

Original Article

Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors

Case Report

Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task

Letter to the Editor

Composite gastrointestinal lymphoma consisting of diffuse large B-cell lymphoma and peripheral T-cell lymphoma

Case Report

A chronic myeloid leukemia patient with atypical karyotype and BCR–ABL e13a3 transcript caused by complex chromosome rearrangement

Case Report

Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits